The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs).
 
Meredith McAdams
No Relationships to Disclose
 
Shannon Swift
No Relationships to Disclose
 
Renee N. Donahue
No Relationships to Disclose
 
Carolina Celades
No Relationships to Disclose
 
Yo-Ting Tsai
Stock and Other Ownership Interests - Moderna Therapeutics
Patents, Royalties, Other Intellectual Property - The Ohio State University (I)
 
Molly Bingham
No Relationships to Disclose
 
Eva Szabo
No Relationships to Disclose
 
Chen Zhao
No Relationships to Disclose
 
Susan Sansone
No Relationships to Disclose
 
Nirmal Choradia
No Relationships to Disclose
 
Meenakshi Shelat
No Relationships to Disclose
 
Joseph Francis O'Donnell
Employment - Promontory Therapeutics
Leadership - Promontory Therapeutics
Stock and Other Ownership Interests - Promontory Therapeutics
 
Tyler David Ames
Employment - Promontory Therapeutics
Stock and Other Ownership Interests - Promontory Therapeutics
Patents, Royalties, Other Intellectual Property - I am an inventor on some patents pertaining to the mechanism or use of PT-112, an anticancer compound being developed by my employer Promontory Therapeutics.
Travel, Accommodations, Expenses - Promontory Therapeutics
 
Brooke Raphael
Employment - Promontory Therapeutics
Stock and Other Ownership Interests - Promontory Therapeutics
 
Seth M. Steinberg
No Relationships to Disclose
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Jeffrey Schlom
Research Funding - Bavarian Nordic (Inst); EMD Serono/Merck (Inst); ImmunityBio (Inst); Incyte (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - If applicable; If applicable (Inst)
 
Arun Rajan
Research Funding - Bayer (Inst); EMD Serono/Merck (Inst); Promontory Therapeutics (Inst)